The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and
tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that it was necessary to strengthen these warnings in the product information and on packaging to better inform healthcare professionals and patients of these known risks.
Summary of the latest safety advice for medicines and medical device users
List of Field Safety Notices from 8 to 12 September 2025.
Exploring the MHRA’s transformational impact on access, experience, and outcomes.
Clinical trial applications that need expert advice from a specialist group or committee.
Annual Report of the Human Medicines Regulations 2012 Advisory Bodies – the Commission on Human Medicines (CHM) and the British Pharmacopoeia Commission.
List of Field Safety Notices from 29 December 2025 to 2 January 2026.
